Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche’s Polivy Among Seven New Drugs On Track For EU-Wide Approval

Conditional Approval In Store For The Lymphoma Treatment

Executive Summary

Seven drugs, including two orphans and two generics, are on track to receive pan-EU approval.

You may also be interested in...



Incyte/MorphoSys Await EU Verdict On Tafasitamab For DLBCL

Is the benefit-risk profile of tafasitamab good enough for it to be recommended for EU-wide marketing approval? Codevelopers Incyte and MorphoSys may find out this week.

EU: Rigel And Jazz Among Hopefuls At CHMP

Rigel Pharmaceuticals and Jazz Pharmaceuticals are among the companies that could find out this week whether their new drug applications at the European Medicines Agency are likely to be approved for marketing across the EU. The EMA's key scientific committee, the CHMP, will also consider applications from Roche and Novartis.

EU: Stakes High For Novartis At Latest CHMP Meeting

Novartis is likely to hear this week whether siponomid and osilodrostat will be recommended for marketing across the EU.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS141209

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel